Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Piramal Pharma Solutions, Plus Therapeutics Ink MSA 
 | Contract Pharma

What are you searching for?

Sign in
Breaking News

Piramal Pharma Solutions, Plus Therapeutics Ink MSA 


Piramal to perform services related to the development, manufacture, and supply of Plus Therapeutics’ RNL-Liposome Intermediate Drug Product.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Piramal Pharma Solutions (PPS), has entered into a Master Services Agreement (MSA) with Plus Therapeutics, Inc. for Piramal to perform services related to the development, manufacture, and supply of Plus Therapeutics’ RNL-Liposome Intermediate Drug Product.

This MSA includes the transfer of analytical methods, development of microbiological methods, process transfer and optimization, intermediate drug product manufacturing, and stability studies. The transfer will be performed at PPS’ facility located in Lexington, KY. It’s anticipated that the MSA will lead to clinical and commercial supply agreements for the drug product.

PPS’ Lexington site provides formulation, development and manufacturing of sterile parenteral drug products with the capability to support New Chemical Entities (NCEs), generics, and molecules that might be following the 505(b)(2) regulatory pathway.

“This agreement represents another significant milestone for Plus, as we work to advance development of RNL as a novel treatment option for patients diagnosed with glioblastoma,” said Marc Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics. “The team at PPS has the knowledge, experience and expertise to support our needs, both now and in the future as we advance RNL towards regulatory approval.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics